• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity.

作者信息

Giannitsas K, Perimenis P, Athanasopoulos A, Gyftopoulos K, Nikiforidis G, Barbalias G

机构信息

Departments of Urology and Medical Physics, Patras University, Patras, Greece.

出版信息

Eur Urol. 2004 Dec;46(6):776-82; discussion 782-3. doi: 10.1016/j.eururo.2004.07.021.

DOI:10.1016/j.eururo.2004.07.021
PMID:15548447
Abstract

OBJECTIVE

To compare the efficacy of tolterodine and oxybutynin in the treatment of specific, according to their urodynamic grade of severity, populations with overactive detrusor.

METHODS

In this open, randomized, two-way crossover study 128 women with urodynamically confirmed, idiopathic detrusor overactivity were recruited. Patients were categorized in 4 grades of severity groups, according to the characteristics of the first overactive detrusor contraction during filling cystometrogram: high volume-low pressure (grade-group I), high volume-high pressure (grade-group II), low volume-low pressure (grade-group III) and low volume-high pressure (grade-group IV). The primary outcome measure was average volume of voided urine per micturition.

RESULTS

107 patients successfully completed the study protocol and were included in the analyses: 40 in group IV, 36 in III, 25 in II and 6 in group I. In groups IV and III both oxybutynin and tolterodine significantly increased the average volume of voided urine per micturition but the differences between the drugs were not significant (p > 0.05). In group II neither of the drugs achieved significant changes in the outcome measure (p > 0.05).

CONCLUSIONS

Tolterodine and oxybutynin are clinically equipotent in treating detrusor overactivity in specific severity groups of patients, although urodynamic effects are somewhat different.

摘要

相似文献

1
Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity.
Eur Urol. 2004 Dec;46(6):776-82; discussion 782-3. doi: 10.1016/j.eururo.2004.07.021.
2
Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.托特罗定与奥昔布宁治疗儿童逼尿肌不稳定的疗效及副作用比较。
Int J Urol. 2006 Feb;13(2):105-8. doi: 10.1111/j.1442-2042.2006.01240.x.
3
Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.膀胱过度活动症的尿动力学检查能否确定治疗成功?一项随机安慰剂对照研究的结果。
BJU Int. 2009 Apr;103(7):931-7. doi: 10.1111/j.1464-410X.2009.08361.x. Epub 2009 Mar 5.
4
Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.缓释托特罗定治疗日本患者膀胱过度活动症的长期安全性、耐受性和疗效
Int J Urol. 2005 May;12(5):456-64. doi: 10.1111/j.1442-2042.2005.01066.x.
5
Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.托特罗定治疗有逼尿肌过度活动迹象的尿急失禁症状儿童:两项随机、安慰剂对照试验的结果
J Urol. 2005 Apr;173(4):1334-9. doi: 10.1097/01.ju.0000152322.17542.63.
6
Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.膀胱过度活动症药物治疗开始后的医疗费用:选择偏倚对成本估算的影响。
Am J Manag Care. 2005 Jul;11(4 Suppl):S130-9.
7
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.评估治疗膀胱过度活动症药物疗效时的日间排尿次数及每次排尿量:随机临床试验结果
Eur Urol. 2007 Aug;52(2):525-30. doi: 10.1016/j.eururo.2007.03.070. Epub 2007 Apr 2.
8
Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.
Eur Urol. 2005 Sep;48(3):478-82. doi: 10.1016/j.eururo.2005.04.023.
9
Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity.托特罗定与安慰剂相比治疗逼尿肌过度活动的临床疗效及安全性。
J Urol. 1999 May;161(5):1551-5.
10
Comparison of fesoterodine and tolterodine in patients with overactive bladder.非索罗定与托特罗定治疗膀胱过度活动症患者的比较。
BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.

引用本文的文献

1
Overactive bladder - 18 years - Part II.膀胱过度活动症 - 18岁 - 第二部分
Int Braz J Urol. 2016 Mar-Apr;42(2):199-214. doi: 10.1590/S1677-5538.IBJU.2015.0367.
2
Persistence and compliance with medication management in the treatment of overactive bladder.膀胱过度活动症治疗中药物管理的持续性与依从性。
Investig Clin Urol. 2016 Mar;57(2):84-93. doi: 10.4111/icu.2016.57.2.84. Epub 2016 Mar 11.
3
Bladder dysfunction in diabetes mellitus.糖尿病中的膀胱功能障碍。
Front Pharmacol. 2010 Nov 16;1:136. doi: 10.3389/fphar.2010.00136. eCollection 2010.
4
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder.抗毒蕈碱药物治疗膀胱过度活动症的临床应用概述。
Adv Urol. 2011;2011:820816. doi: 10.1155/2011/820816. Epub 2011 Jun 7.
5
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.抗毒蕈碱药物治疗膀胱过度活动症的不良事件评估:网络荟萃分析方法。
PLoS One. 2011 Feb 23;6(2):e16718. doi: 10.1371/journal.pone.0016718.
6
Pharmacotherapy of urinary incontinence.尿失禁的药物治疗
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Apr;20(4):475-82. doi: 10.1007/s00192-008-0761-1. Epub 2008 Nov 12.